title: Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
abstract: Kaposi sarcoma (KS) is a vascular tumour of endothelial cell origin, associated with human herpes virus 8. It develops in one of four clinical settings, one of which is iatrogenic immunosuppression. We present the case of a 46year-old man with relapsing-remitting multiple sclerosis who developed KS in the context of fingolimod use. To our knowledge, this is the second reported case of KS in a fingolimod-treated individual. This case highlights potential risks associated with immunosuppression with this medicine and ongoing need for vigilance in assessing for such complications.
authors.affiliation: St. Vincent's Hospital, Neurology Department, 390 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia. Electronic address: walkersuse@hotmail.com.
authors.forename: Susan
authors.initials: S
authors.lastname: Walker
authors.affiliation: St. Vincent's Hospital, Neurology Department, 390 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia.
authors.forename: Bruce
authors.initials: B
authors.lastname: Brew
mesh_terms: D000068876:Fingolimod Hydrochloride / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy*; D012514:Sarcoma, Kaposi / Q000150:complications / Q000209:etiology*
chemical_list: D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride
keywords: Adverse effect; Fingolimod; Kaposi sarcoma; Malignancy; Multiple sclerosis